000281352 001__ 281352
000281352 005__ 20251012002031.0
000281352 0247_ $$2doi$$a10.1002/brb3.70878
000281352 0247_ $$2pmid$$apmid:40958409
000281352 0247_ $$2pmc$$apmc:PMC12441002
000281352 0247_ $$2altmetric$$aaltmetric:181698257
000281352 037__ $$aDZNE-2025-01099
000281352 041__ $$aEnglish
000281352 082__ $$a610
000281352 1001_ $$aBeckmann, Janna$$b0
000281352 245__ $$aAnxiety in Myasthenia Gravis Patients Throughout the COVID-19 Pandemic-Prevalence, Risk Factors, and Association With Vaccination Status.
000281352 260__ $$aMalden, Mass.$$bWiley$$c2025
000281352 3367_ $$2DRIVER$$aarticle
000281352 3367_ $$2DataCite$$aOutput Types/Journal article
000281352 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1759825797_17321
000281352 3367_ $$2BibTeX$$aARTICLE
000281352 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281352 3367_ $$00$$2EndNote$$aJournal Article
000281352 520__ $$aA high prevalence of COVID-19-related anxiety was observed among the general population during the COVID-19 pandemic. Patients with myasthenia gravis (MG) might be at higher risk for COVID-19-related anxiety due to immunosuppressive therapy in the majority of cases and risk of myasthenic exacerbation in case of an infection. This prospective longitudinal study assessed COVID-19-related anxiety in MG patients over 2 years of the pandemic and its association with MG-specific factors (e.g., disease severity, immunosuppressive medication) and with vaccination status.A three-wave longitudinal online survey was conducted from May 2020 to February 2022, including a total of 648 adult MG patients. Descriptive, univariate, and multivariate analyses were performed to assess COVID-19-related and MG-related anxiety, associated MG-specific factors, and association with vaccination status.COVID-19-related anxiety was frequent, with the most pronounced fear being risk for one's own health (overall 83.9%). Anxiety was influenced by MG diagnosis (overall 75.1%), especially by fear of exacerbation of myasthenic symptoms and greater risk of infection due to immunosuppressive therapy. Female sex and treatment with immunosuppressive medication, including rituximab, were associated with an increased concern for one's own health. Fear for one's own health was the only factor associated with vaccination status.COVID-19-related anxiety was prevalent among MG patients. An ongoing psychological impact is likely and highlights the need for anxiety screening in clinical practice. Our findings emphasize the importance of addressing mental health challenges during future pandemics.
000281352 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281352 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281352 650_7 $$2Other$$aautoimmune disease
000281352 650_7 $$2Other$$acorona
000281352 650_7 $$2Other$$afear
000281352 650_7 $$2Other$$aimmunosuppressive treatment
000281352 650_7 $$2NLM Chemicals$$aImmunosuppressive Agents
000281352 650_2 $$2MeSH$$aHumans
000281352 650_2 $$2MeSH$$aMyasthenia Gravis: psychology
000281352 650_2 $$2MeSH$$aMyasthenia Gravis: epidemiology
000281352 650_2 $$2MeSH$$aMyasthenia Gravis: drug therapy
000281352 650_2 $$2MeSH$$aMyasthenia Gravis: complications
000281352 650_2 $$2MeSH$$aCOVID-19: psychology
000281352 650_2 $$2MeSH$$aCOVID-19: epidemiology
000281352 650_2 $$2MeSH$$aFemale
000281352 650_2 $$2MeSH$$aMale
000281352 650_2 $$2MeSH$$aAnxiety: epidemiology
000281352 650_2 $$2MeSH$$aAnxiety: etiology
000281352 650_2 $$2MeSH$$aAnxiety: psychology
000281352 650_2 $$2MeSH$$aMiddle Aged
000281352 650_2 $$2MeSH$$aRisk Factors
000281352 650_2 $$2MeSH$$aPrevalence
000281352 650_2 $$2MeSH$$aAdult
000281352 650_2 $$2MeSH$$aAged
000281352 650_2 $$2MeSH$$aLongitudinal Studies
000281352 650_2 $$2MeSH$$aProspective Studies
000281352 650_2 $$2MeSH$$aVaccination: psychology
000281352 650_2 $$2MeSH$$aVaccination: statistics & numerical data
000281352 650_2 $$2MeSH$$aImmunosuppressive Agents: therapeutic use
000281352 650_2 $$2MeSH$$aImmunosuppressive Agents: adverse effects
000281352 650_2 $$2MeSH$$aSARS-CoV-2
000281352 7001_ $$aPetzold, Moritz$$b1
000281352 7001_ $$aBetzler, Felix$$b2
000281352 7001_ $$aStröhle, Andreas$$b3
000281352 7001_ $$aBendau, Antonia$$b4
000281352 7001_ $$aDusemund, Carla$$b5
000281352 7001_ $$0P:(DE-2719)2810273$$aPetzold, Gabor C$$b6$$udzne
000281352 7001_ $$aMeisel, Andreas$$b7
000281352 7001_ $$aHoffmann, Sarah$$b8
000281352 773__ $$0PERI:(DE-600)2623587-0$$a10.1002/brb3.70878$$gVol. 15, no. 9, p. e70878$$n9$$pe70878$$tBrain and behavior$$v15$$x2162-3279$$y2025
000281352 8564_ $$uhttps://pub.dzne.de/record/281352/files/DZNE-2025-01099.pdf$$yOpenAccess
000281352 8564_ $$uhttps://pub.dzne.de/record/281352/files/DZNE-2025-01099.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281352 909CO $$ooai:pub.dzne.de:281352$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000281352 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810273$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000281352 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281352 9141_ $$y2025
000281352 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-06
000281352 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281352 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN BEHAV : 2022$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-06$$wger
000281352 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-08-08T17:05:29Z
000281352 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-08-08T17:05:29Z
000281352 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281352 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-06
000281352 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-06
000281352 9201_ $$0I:(DE-2719)1013020$$kAG Petzold$$lVascular Neurology$$x0
000281352 980__ $$ajournal
000281352 980__ $$aVDB
000281352 980__ $$aUNRESTRICTED
000281352 980__ $$aI:(DE-2719)1013020
000281352 9801_ $$aFullTexts